DuPont practically has its own news agency, and today it released a major piece about the benefits of biotechnology, including those tied to bioethics principles. If you dig you find their new advisory board, with links to a bioethics policy and perspectives of board members.
Labels: bioethics policy, bioethics principles, biotechnology, DuPont, pharmaceutical industry